Introduction {#s1}
============

Head and neck squamous cell carcinoma (HNSCC) is expected to be responsible for ∼61 000 new cases and \>13 000 deaths throughout 2016 in the USA alone ([@CIT0001]). Considerable morbidity is associated with HNSCC as surgery and/or definitive radiation can result in disfigurement, difficulty swallowing, breathing and speaking ([@CIT0002]). Established risk factors include alcohol consumption, tobacco use and human papillomavirus (HPV) infection and diet, oral hygiene and marijuana use have also been implicated ([@CIT0003]). Patients diagnosed with late stage disease have \>50% chance of recurrence or development of distant metastases therefore improvement of effective risk stratification and early detection strategies are critical toward reducing patient morbidity and mortality ([@CIT0008]).

Genetic variation in protein-coding regions directing alcohol metabolism, DNA repair, apoptosis, cell cycle control, mitochondrial function and at HPV-related pathways has been associated with HNSCC risk ([@CIT0009]). A recent Genome-wide association study (GWAS) of oral cavity cancer and oropharyngeal cancer identified seven novel loci associated with these cancer sites ([@CIT0013]). While variation in protein-coding regions has received much attention in such studies, most disease associated variants lie within non-coding regions ([@CIT0014]). Polymorphisms within microRNA (miRNA) targets sites, miRNA seed sites and miRNA processing genes can modify miRNA--mRNA binding, as well as create or destroy target sites entirely ([@CIT0015]). However, such miRNA-related SNPs (miR-SNPs) are generally poorly represented on---and/or in low linkage disequilibrium (LD) with---SNPs on or imputed using Genome-wide association study (GWAS) arrays ([@CIT0016]), and although candidate gene studies have identified miR-SNPs associated with HNSCC susceptibility ([@CIT0017]), comprehensive evaluation of the relation between miR-SNPs and HNSCC susceptibility has yet to be investigated. To address these issues, we conducted a genome-scale evaluation of the association between miR-SNPs and HNSCC susceptibility, utilizing a novel genotyping array containing validated and predicted miR-SNPs at all levels of the miRNA pathway.

Materials and methods {#s2}
=====================

Study participants {#s3}
------------------

To identify miR-SNPs associated with HNSCC susceptibility, we obtained and analyzed data from two independent population-based case--control studies of HNSCC using a discovery (Massachusetts study; *n*, cases = 904, *n*, controls = 1051) and validation phase (M.D. Anderson study; *n*, cases = 1338, *n*, controls = 1356) approach. All subjects provided written informed consent as approved by the Institutional Review Boards of the participating institutions. For the Massachusetts study, which has been described previously ([@CIT0010]), incident cases of HNSCC were identified at nine hospitals in the Boston, MA, metropolitan area between 1999--2003 (Phase I) and 2006--2011 (Phase II). The state cancer registry confirmed \>95% of incident cases in the study area were captured. Histology was reported by participating hospitals' pathologists and confirmed by an independent study pathologist. Control subjects were matched to cases by age (±3 years), sex and town of residence. Demographic and exposure data were collected using self-administered questionnaires that were reviewed by trained study interviewers, and clinical information was obtained through medical chart reviews.

For the validation phase, histopathologically confirmed incident cases of HNSCC were recruited at The University of Texas M.D. Anderson Cancer Center between December 1996 and 2008. Details of patient recruitment to the study have been described previously ([@CIT0024]). Hospital visitors at the M.D. Anderson Cancer Center over the same time were recruited as cancer-free controls and completed a questionnaire so that demographic and exposure data could be collected. Cases and controls were matched based on age and sex. Although categorical indicators of tobacco and alcohol use were available, continuous measures of these exposures (lifetime pack-years smoked and lifetime average number of drinks per week) were not available for most genotyped subjects. International Classification of Disease, Ninth Revision (ICD-9) codings and relevant pathological analyses were used to assign HNSCC cases to one of three groups; oral cavity, pharyngeal or laryngeal cancer. HNSCC cases included ICD-9 diagnosis codes 141, 143--146, 148, 149 and 161. For site-specific analyses cases with diagnosis codes were classified with ICD-9 codes as follows: oral cavity; 141.1--141.5, 141.8, 141.9, 143--145.2, 145.5--145.9, pharyngeal; 141.0, 141.6, 145.3, 145.4, 146, 148, 149.0, 149.1, laryngeal; 161.

Genotyping {#s4}
----------

DNA from Massachusetts study subjects was extracted from whole blood or buccal cells using the QIAamp DNA mini kit (Qiagen) and was genotyped using the Axiom miRNA Target Site Genotyping Array (Affymetrix). The standard array (no marker customization) was used. To reduce the burden of multiple testing, we limited our analyses to the 40 034 markers present at a MAF ≥5% (after quality control). In total, the array interrogates \~238 000 SNPs and indels in miRNAs, miRNA regulatory regions, miRNA target sites and miRNA processing proteins. Five online databases were used to select markers for the array; PolymiRTS ([@CIT0025]), dPORE ([@CIT0026]), Patrocles ([@CIT0027]), miRNASNP ([@CIT0028]) and [microRNA.org](http://microRNA.org) ([@CIT0029]). The array also includes \~18 100 haplotype tagging miR-SNPs predicted to affect miRNA binding in mRNA 3ʹUTRs, identified by Thomas *et al.* ([@CIT0030]). Quality control was performed according to the Axiom Best Practice Genotyping Analysis Workflow. Two samples below the Dish QC (DQC) metric threshold of 0.82, and 24 samples below the call rate threshold of 97% were excluded from analysis. About 16 597 markers fell below the suggested thresholds for SNP QC and were omitted. Of the remaining markers, 40 286 were present in the discovery population at a MAF ≥5%. 252 SNPs deviated from Hardy--Weinberg equilibrium (HWE) in Caucasian control study subjects (*P* \< 1 × 10^--3^) and were removed, leaving the 40,034 markers for the discovery phase. Validation genotyping of DNA from M.D. Anderson study subjects was performed using the MassARRAY iPLEX gold assay (Sequenom). In the validation population 288 subjects with a call rate of \<95%, four variants deviating from HWE in Caucasian controls, and monomorphic variants were removed.

Statistical analysis {#s5}
--------------------

Unconditional multivariable logistic regression for the association between miR-SNP genotype and HNSCC risk was performed using *R Statistical Software version 3.3.0* to calculate odds ratios (ORs) and 95% confidence intervals (95% CI), assuming a dominant model of inheritance. HWE was calculated with exact tests using the HWExact function (pvaluetype = \'dost\') from *R* package *HardyWeinberg*. Markers deviating from HWE at *P* \< 1 × 10^--3^ were omitted. Statistical models in the discovery phase were adjusted for age (≤50, \>50 to ≤60, \>60 to ≤70, \>70), sex (male, female), race (Caucasian, other), HPV serology (positive/negative for any of HPV types; HPV16, 18, 33, 51), alcohol consumption (lifetime average number of drinks per week) and tobacco use (lifetime pack-years). Subjects were ordered into discrete groups based on the population quartile distribution of alcohol consumption (≤1, \>1 to ≤6, \>6 to ≤31, \>31) and tobacco use (≤2, \>2 to ≤6, \>6 to ≤14, \>14). Genomic inflation factor λ was calculated using the *R* package *GenABEL* ([@CIT0031]). To select markers for the validation phase, the strongest associations from each analysis, based on adjusted *P* values, were pruned using pairwise LD patterns determined from all available study participants selecting the two SNPs in lowest pairwise LD per gene calculated using the *R* package *genetics*. 32, 27, 28 and 27 markers were selected for validation genotyping in the overall, oral cavity cancer, pharyngeal cancer and laryngeal cancer-specific analyses, respectively (validation marker lists Supplementary Tables 1--4, available at *Carcinogenesis* Online), and tested with a joint analysis approach ([@CIT0032]). Models for the validation population and joint analyses were adjusted for age, sex, race and smoking status (current, former, never). Extensive data for continuous measures of tobacco and alcohol consumption were not available in validation phase subjects. We considered validated variants as those with *P* \< 1 × 10^-3^ in the joint analysis, a lower *P* in the joint analyses than the discovery phase analyses, and a consistent predicted direction of effect across study populations. Validated variants were selected for additional follow up analyses. The LD-pruning function in PLINK was used to determine the number of effectively independent variants in each analysis, using a 100-variant window size, a five-variant window shift and an *r*^2^ of 0.1. Population-specific genome-wide significance thresholds were based on Bonferroni correction (*P* = 3.5 × 10^--6^ to 1 d.p.).

Identification of HNSCC-associated loci predicted to disrupt miRNA target sites {#s6}
-------------------------------------------------------------------------------

Genomic coordinates for all available miRNA target site predictions made using the miRanda algorithm and scored for meaningful downregulation of target genes using the mirSVR algorithm \[downloaded from the microRNA.org database (<http://www.microrna.org/microrna/home.do>)\] were intersected with hg19 coordinates for HNSCC-associated SNPs ([@CIT0029],[@CIT0033]). Low confidence interactions (mirSVR score \>−0.1) were omitted ([@CIT0034]). Three online databases; PolymiRTSv3.0 ([@CIT0025]), miRNASNP ([@CIT0028]) and MirSNP ([@CIT0035]) were mined to identify miRNA target sites that may be disrupted by HNSCC-associated loci. PolymiRTSv3.0 utilizes TargetScan context+ scores to rank predicted miRNA target sites. Context+ scores predict the binding of a miRNA over a 3ʹUTR. Differences between context+ scores calculated using the reference and derived alleles for SNPs are provided by PolymiRTSv3.0. More negative context+ score differences suggest an increased likelihood that a variant disrupts miRNA targeting. Percentile ranks for context+ score differences were calculated based on all available scores. Lower percentile ranks indicate interactions more likely to be disrupted by genetic variation. The miRNASNP database (<http://www.bioguo.org/miRNASNP/index.php>) invokes the TargetScan and miRanda algorithms to make predictions of SNP effects on miRNA binding ([@CIT0028]). MirSNP (<http://bioinfo.bjmu.edu.cn/mirsnp/search/>) utilizes the miRanda algorithm for miRNA target site prediction to determine the likely consequences of a given SNP (decrease/break or enhance/create miRNA target sites) ([@CIT0035]). All available predictions were downloaded from each database and queried for the SNPs associated with HNSCC in this study.

TCGA miRNA expression analyses {#s7}
------------------------------

miRNA isoform expression quantification from miRNA-seq analyses of The Cancer Genome Atlas (TCGA) HNSCC normal (*n* = 44) and primary tumor tissue (*n* = 523) samples was downloaded from the Genomic Data Commons Data Portal. To obtain strand specific miRNA expression for genes producing two miRNAs from the same precursor, miRBase accessions were used to determine expression of the relevant miRNA isoform. Average miRNA expression (miRNA mapped reads per million) across all samples was determined and restricted to miRNAs predicted to target genomic loci overlapping SNPs associated with HNSCC risk in this study. Percentile scores were calculated for the log~2~ transformed average gene expression values. miRNA--mRNA interactions identified from *in silico* analyses for which miRNA expression across all normal and tumor tissue was not available in isoform expression quantification files were omitted.

Code availability {#s8}
-----------------

R Code used to perform the analyses presented in this study will be made available upon request to the authors.

Data availability {#s9}
-----------------

Submission of genotypes and phenotypes to dbGAP is in process and an accession number was not available at the time of going to press.

Results {#s10}
=======

Discovery phase associations of miR-SNPs with HNSCC risk {#s11}
--------------------------------------------------------

To investigate the association of miR-SNPs across the genome with HNSCC risk, we genotyped \~238 000 SNPs in miRNA target sites, miRNA genes, and genes in the miRNA biogenesis pathway in a population-based case control study based in Massachusetts with the Affymetrix Axiom miRNA Target Site Array. For discovery, we tested the associations of 40 034 genetic variants genotyped using the Affymetrix miRTS array MAF ≥5%\], with overall and tumor site-specific (oral cavity, pharyngeal, laryngeal) HNSCC risk, in 1051 controls and 904 cases from the Massachusetts study ([Table 1](#T1){ref-type="table"}). We applied unconditional logistic regression adjusted for age at diagnosis, sex, race, HPV seropositivity, tobacco consumption and alcohol consumption. Across the overall and site-specific analyses, the strongest associations were observed for rs9791083 (overall HNSCC, *CSNK1A1*, OR; 0.73, 95% CI; 0.53--0.79), rs2018329 (oral cavity cancer, *RUNX1*, OR; 0.43, 95% CI; 0.19--0.64), rs59858117 (pharyngeal cancer, *ATG3*, OR; 2.47, 95% CI; 1.62--3.76) and rs221347 (laryngeal cancer, *HADH*, OR; 2.74, 95% CI; 1.79--4.19). Generally, the strongest associations with HNSCC risk were observed for overall HNSCC and oral cavity cancer, with 41 and 50 variants at an adjusted *P \<* 1 × 10^--3^, respectively, compared to 35 and 33 variants with adjusted *P* values below this threshold in the pharyngeal and laryngeal cancer analyses. Genomic inflation factor λ was calculated to measure *P* value inflation for the adjusted analyses and was close to 1 for all adjusted analyses, indicating minimal contribution of population stratification (Supplementary Figure 1, available at *Carcinogenesis* Online). Compared with the analysis of overall risk, effect size estimates in the site-specific analyses were generally larger (Supplementary Figure 2, available at *Carcinogenesis* Online), particularly for laryngeal cancer associated variants. Summary statistics for all associations tested in the discovery phase are available in Supplementary Datasets 1--4, available at *Carcinogenesis* Online.

###### 

Clinical and pathological characteristics of study subjects

                                    Controls, *n* (%)   Cases, *n* (%)                                            
  --------------------------------- ------------------- ---------------- ------------- ------------ ------------- -------------
  Age at diagnosis                                                                                                
   ≤50                              169 (16.1)          441 (32.5)       610 (25.3)    189 (20.9)   366 (27.4)    555 (24.8)
   \>50 to ≤60                      345 (32.8)          468 (34.5)       813 (33.8)    320 (35.4)   486 (36.3)    806 (36)
   \>60 to ≤70                      331 (31.5)          316 (23.3)       647 (26.9)    251 (27.8)   334 (25)      585 (26.1)
   \>70                             206 (19.6)          131 (9.7)        337 (14)      144 (15.9)   152 (11.4)    296 (13.2)
  Sex                                                                                                             
   Female                           276 (26.3)          360 (26.5)       636 (26.4)    233 (25.8)   315 (23.5)    548 (24.4)
   Male                             775 (73.7)          996 (73.5)       1771 (73.6)   671 (74.2)   1023 (76.5)   1694 (75.6)
  Race                                                                                                            
   Caucasian                        943 (89.7)          1160 (85.5)      2103 (87.4)   847 (93.7)   1212 (90.6)   2059 (91.8)
   Other                            108 (10.3)          196 (14.5)       304 (12.6)    57 (6.3)     126 (9.4)     183 (8.2)
  Smoking status                                                                                                  
   Current                          129 (12.3)          165 (12.2)       294 (12.2)    102 (11.3)   493 (36.8)    595 (26.5)
   Former                           489 (46.5)          405 (29.9)       894 (37.1)    539 (59.6)   437 (32.7)    976 (43.5)
   Never                            419 (39.9)          573 (42.3)       992 (41.2)    223 (24.7)   404 (30.2)    627 (28)
   Missing                          14 (1.3)            213 (15.7)       227 (9.4)     40 (4.4)     4 (0.3)       44 (2)
  HPV16, 18, 33, 51 positivity^a^                                                                                 
   Positive                         360 (34.3)                                         564 (62.4)                 
   Negative                         691 (65.7)                                         340 (37.6)                 
  Tumor stage                                                                                                     
   Stages I and II                                                                     243 (26.9)   331 (24.7)    574 (25.6)
   Stages III and IV                                                                   604 (66.8)   1007 (75.3)   1611 (71.9)
   Missing                                                                             57 (6.3)     0 (0)         57 (2.5)
  Tumor site                                                                                                      
   Oral cavity                                                                         328 (36.3)   384 (28.7)    712 (31.8)
   Pharynx                                                                             431 (47.7)   734 (54.9)    1165 (52)
   Larynx                                                                              145 (16)     220 (16.4)    365 (16.3)

^a^Any seropositivity for listed high-risk (HR) HPV serotypes (16, 11, 33 or 55), was only available for Massachusetts study subjects.

Validation phase associations of miR-SNPs with HNSCC risk {#s12}
---------------------------------------------------------

An independent study population of incident HNSCC conducted at The University of Texas M.D. Anderson Cancer Center was used to validate findings from the discovery phase. MAFs of the 119 variants selected for validation were highly concordant across study populations (Supplementary Figure 3, available at *Carcinogenesis* Online). Eight associations from the discovery phase were validated in a joint analysis adjusting for age at diagnosis, sex, race and smoking status ([Table 2](#T2){ref-type="table"}; Supplementary Tables 1--4, available at *Carcinogenesis* Online). Supplementary Figure 4, available at *Carcinogenesis* Online, shows the relationship between effect size (ORs), MAF and statistical significance for the validated associations. For overall risk of HNSCC, rs7834169 upstream of *MIR548H4*, was replicated ([Table 2](#T2){ref-type="table"}), and does not overlap with known enhancer or promoter marks (Supplementary Table 5, available at *Carcinogenesis* Online). In the discovery phase, modest associations were observed for variants in pairwise LD with rs7834169 (Supplementary Figure 5A, available at *Carcinogenesis* Online), and conditional analysis revealed that they were dependent upon rs7834169 (Supplementary Figure 6A, available at *Carcinogenesis* Online). *MIR548H4* was not expressed in the analysis of normal tissue from TCGA HNSCC subjects.

###### 

Summary statistics for miR-SNPs associated with HNSCC susceptibility

  SNP             Chr:pos^c^    Associated gene^d^   Genomic context^e^   EAF (cases/ controls)^f^   Discovery phase^a^   Validation phase^b^   Joint analysis^b^                                 
  --------------- ------------- -------------------- -------------------- -------------------------- -------------------- --------------------- ------------------- --------- ------------------- ---------
  Overall HNSCC                                                                                                                                                                                   
   rs7834169      8:26910291    *MIR548H4*           Intergenic           0.07/0.11                  0.60 (0.46--0.78)    1.3E−04               0.80 (0.63--1.00)   4.8E−02   0.70 (0.59--0.82)   1.7E−05
  Oral cavity                                                                                                                                                                                     
   rs16914640     12:9822387    *CLEC2D*             Missense             0.19/0.14                  1.70 (1.27--2.27)    3.6E−04               1.46 (1.12--1.91)   5.7E−03   1.60 (1.32--1.94)   1.5E−06
   rs7834169      8:26910291    *MIR548H4*           Intergenic           0.07/0.11                  0.49 (0.33--0.73)    3.5E−04               0.68 (0.48--0.96)   2.8E−02   0.57 (0.44--0.73)   1.5E−05
   rs1134367      16:27232883   *KDM8*               3ʹUTR                0.46/0.51                  0.58 (0.43--0.77)    2.0E−04               0.74 (0.56--0.97)   2.9E−02   0.68 (0.56--0.82)   9.5E−05
   rs1373756      18:49786306   *DCC*                Intergenic           0.08/0.12                  0.49 (0.32--0.73)    5.9E−04               0.68 (0.48--0.96)   2.7E−02   0.61 (0.47--0.79)   1.6E−04
   rs7306991      12:9810451    *LOC374443*          ncRNA                0.18/0.13                  1.63 (1.22--2.18)    8.7E−04               1.35 (1.02--1.77)   3.5E−02   1.45 (1.20--1.76)   1.6E−04
  Laryngeal                                                                                                                                                                                       
   rs221347       4:108955622   *HADH*               3ʹUTR                0.14/0.10                  2.74 (1.79--4.19)    3.2E−06               1.46 (0.97--2.19)   7.0E−02   1.96 (1.48--2.61)   2.9E−06
   rs4975616      5:1315660     *CLPTM1L*            Intergenic           0.37/0.45                  0.52 (0.35--0.76)    8.1E−04               0.76 (0.54--1.07)   1.2E−01   0.64 (0.50--0.82)   3.8E−04

^a^Analysis adjusted for age at diagnosis, sex, race, HPV seropositivity (16, 11, 33 or 55), tobacco use (lifetime pack-years smoked) and alcohol consumption (average drinks per week).

^b^Analysis adjusted for age at diagnosis, sex, race and smoking status (never, former and current).

^c^chr, chromosome; pos, position, according to NCBI Genome Build 37 (hg19).

^d^Gene that variant is located within or associated with \[closest gene according to NCBI Genome Build 37 (hg19)\].

^e^UTR, untranslated region; ncRNA, non-coding RNA variant.

^f^EAF, Effect allele frequencies calculated using all study subjects.

In the analysis of oral cavity cancer risk, four miR-SNPs were validated ([Table 2](#T2){ref-type="table"}). rs16914640, located within exon 1 of natural killer cell receptor *CLEC2D*, was associated with increased oral cavity cancer risk ([Table 2](#T2){ref-type="table"}, Supplementary Figure 4, available at *Carcinogenesis* Online). Another regional variant (rs7306991) in a pseudogene of *CLEC2D* replicated its association with oral cavity cancer, though these SNPs were not in LD ([Table 2](#T2){ref-type="table"}; Supplementary Figure 5F, available at *Carcinogenesis* Online). rs1134367, located in the 3ʹUTR of histone demethylase *KDM8*, was associated with reduced risk of oral cavity cancer ([Table 2](#T2){ref-type="table"}, Supplementary Figure 4, available at *Carcinogenesis* Online). Ancestry informative marker rs1373756 ([Table 2](#T2){ref-type="table"}) was also associated with oral cavity cancer risk.

While no variants were validated in the joint analyses of pharyngeal cancer risk, we identified two variants associated with risk of laryngeal cancer; rs221347 (3ʹUTR, *HADH*) and rs4975616 (upstream, *CLPTM1L*) ([Table 2](#T2){ref-type="table"}). rs221347 was the strongest association observed in any of the discovery phase analyses. Stratified analyses suggested potential effect modification of the rs221347 association by smoking status, as moderate to strong levels of association with laryngeal cancer risk were observed in never and former smokers, while no association was seen for current smokers across any of the study phases (Supplementary Table 6, available at *Carcinogenesis* Online). rs4975616 is located in known cancer risk locus 5p15.33 and was included on the genotyping array as part of a set of known disease-associated loci curated from the National Human Genome Research Institute (NHGRI) GWAS catalog. Similar results were observed in sensitivity analyses of overall and site-specific HNSCC risk restricted to Caucasian subjects (Supplementary Table 7, available at *Carcinogenesis* Online).

Predicted miRNA--mRNA interactions at HNSCC-associated loci {#s13}
-----------------------------------------------------------

To identify miRNA--mRNA interactions disrupted by genetic variation, we intersected predicted miRNA target sites made using the miRanda algorithm with HNSCC associated SNPs outlined in [Table 2](#T2){ref-type="table"} ([@CIT0029],[@CIT0033]). Additionally, we calculated miRNA expression percentiles using miRNA-seq data of normal and primary tumor head and neck tissue samples from TCGA. We identified multiple high confidence predicted miRNA target sites at HNSCC-associated loci, many of which are expressed at a high level in normal and/or tumor head and neck tissue samples ([Table 3](#T3){ref-type="table"}). Predicted target sites for miR-3166 were identified for two sequences aligned to *CLEC2D* at rs16914640. Predicted miRNA target sites miR-3148, miR-605, miR-619 and miR-875-3p were identified for sequences aligned to *LOC374443* at rs7306991 ([Table 3](#T3){ref-type="table"}). Binding sites for miR-3136 were identified in *KDM8* at rs1134367, and six miRNAs were predicted to target *HADH* at rs221347, two of which were expressed at or above the 73rd percentile in normal head and neck tissues, and at or above the 82nd percentile in tumor tissues ([Table 3](#T3){ref-type="table"}). These data highlight multiple miRNA-mRNA interactions with potential to be disrupted by genetic variation at the HNSCC-associated loci identified in this study.

###### 

miRanda/mirSVR predicted miRNA--mRNA interactions for SNPs associated with HNSCC risk

  SNP          Accession^a^   Gene^b^       Allele^c^   miRNA^d^      mirSVR score   miRNA expression percentile^e^   
  ------------ -------------- ------------- ----------- ------------- -------------- -------------------------------- --------
  rs16914640   AK310554       *CLEC2D*      C           miR-3166      −0.142         0.42                             0.37
               BC063128       *CLEC2D*      C           miR-3166      −0.134         0.42                             0.37
  rs1134367    NM_001145348   *KDM8*        T           miR-3136      −0.246         0.51                             0.66
               AK308499       *KDM8*        T           miR-3136      −0.168         0.51                             0.66
  rs7306991    AY084051       *LOC374443*   A           miR-3148      −0.296         0.01                             0.19
               AY084051       *LOC374443*   A           miR-605       −0.232         0.62                             0.56
               NR_002814      *LOC374443*   A           miR-3148      −0.214         0.01                             0.19
               NR_002814      *LOC374443*   A           miR-605       −0.165         0.62                             0.56
               AY084051       *LOC374443*   A           miR-619       −0.127                                          0.12
               AY084051       *LOC374443*   A           miR-875-3p    −0.114                                          0.67
  rs221347     NM_005327      *HADH*        T           miR-548g      −1.131                                          0.43
               NM_005327      *HADH*        T           miR-3065-5p   −0.910         0.78                             0.82
               NM_005327      *HADH*        T           miR-105       −0.134         0.73                             0.92
               NM_005327      *HADH*        T           miR-548a-3p   −0.107                                          \<0.01
               NM_005327      *HADH*        T           miR-548e      −0.106         0.59                             0.62
               NM_005327      *HADH*        T           miR-548f      −0.106         0.06                             0.78

^a^RefSeq, NCBI or GenBank Transcript/sequence identifiers.

^b^Gene location of variant according to NCBI Genome Build 37 (hg19).

^c^Allele of SNP associated with miRNA--mRNA interaction.

^d^miRBase IDs ([www.mirbase.org](http://www.mirbase.org)) of miRs known or predicted to target-associated gene.

^e^TCGA-HNSCC miRNA expression from normal (*n* = 44) and tumor (*n* = 523) tissue samples. Expression percentiles for log2-transformed miRNA-mapped reads per million were calculated based on the distribution of all available sequenced miRNAs.

Predicted disruption of miRNA--mRNA interactions by HNSCC-associated miR-SNPs {#s14}
-----------------------------------------------------------------------------

To determine if genetic variation at the HNSCC-associated loci may alter miRNA--mRNA interactions, we used three databases on predicted effects of genetic variation at miRNA-related loci (PolymiRTSv3.0, miRNASNP and MirSNP). For the miRNAs whose binding was predicted to be disrupted at risk-associated loci miRNA expression percentiles were calculated as above. Genetic variation at rs1134367 was predicted to disrupt binding of 25 miRNAs to *KDM8* ([Table 4](#T4){ref-type="table"}). Notably, context+ score differences predicting the effects of miR-149-3p, miR-4728-5p and miR-6883-5p binding to *KDM8* were all in the 2nd percentile of all context+ scores obtained from the PolymiRTS database, indicating with high likelihood that the miRNA target site is disrupted by rs1134367 ([Table 4](#T4){ref-type="table"}). The effects of rs1134367 on miR-149-3p, miR-4728-5p and miR-6883-5p binding to *KDM8* were concordant with predicted effects from the miRNASNP and MirSNP databases and all three miRNAs were among the most abundantly expressed in either normal head and neck tissue, or primary HNSCC tumor tissue samples, or both. Six significant eQTLs have been documented for rs1134367 with *KDM8* over a range of tissues (Supplementary Table 8, available at *Carcinogenesis* Online), consistent with the hypothesis that rs1134367 alters miRNA-dependent *KDM8* regulation. In addition, four miRNA target sites in *HADH* were predicted to be disrupted by rs221347. Presence of the T allele for rs221347 was predicted to create a binding site for miR-548g-3p. The context+ score difference for the effects of rs221347 on miR-548g-3p binding to *HADH* were in the top 7% of scores. A very high confidence binding site for miR-548g-3p in *HADH* was also predicted by miRanda/mirSVR ([Table 3](#T3){ref-type="table"}). These data indicate miRNA-related genetic variation at HNSCC risk-associated rs1134367 and rs221347 alters miRNA-dependent gene regulation of *KDM8* and *HADH* in normal head and neck tissue, as well as primary HNSCC tumor tissue.

###### 

Predicted effects of SNPs associated with HNSCC risk upon miRNA--mRNA interactions

  SNP         Accession^a^   Gene^b^   Allele^c^   miRNA^d^       Context + score difference (percentile)^e^   Predicted SNP effect (miRNASNP)   Predicted SNP effect (MirSNP)   miRNA expression (percentile)^f^   
  ----------- -------------- --------- ----------- -------------- -------------------------------------------- --------------------------------- ------------------------------- ---------------------------------- --------
  rs1134367   NM_001145348   *KDM8*    C           miR-149-3p     0.02                                         Gain                              Create                          0.78                               0.78
              NM_024773      *KDM8*    C           miR-149-3p     0.02                                         Gain                              Create                          0.78                               0.78
              NM_001145348   *KDM8*    C           miR-30b-3p     0.39                                         Gain                              Create                          0.79                               0.79
              NM_024773      *KDM8*    C           miR-30b-3p     0.39                                         Gain                              Create                          0.79                               0.79
              NM_001145348   *KDM8*    C           miR-3689c      0.42                                         Gain                              Create                                                             0.31
              NM_024773      *KDM8*    C           miR-3689c      0.42                                         Gain                              Create                                                             0.31
              NM_001145348   *KDM8*    T           miR-4779                                                    Gain                                                              0.07                               0.27
              NM_024773      *KDM8*    T           miR-4779                                                    Gain                              Create                          0.07                               0.27
              NM_001145348   *KDM8*    T           miR-4536-5p    0.28                                         Gain                              Create                          0.59                               0.12
              NM_024773      *KDM8*    C           miR-4536-5p    0.28                                         Loss                              Break                           0.59                               0.12
              NM_001145348   *KDM8*    C           miR-4728-5p    0.02                                         Gain                              Create                                                             0.49
              NM_024773      *KDM8*    C           miR-4728-5p    0.02                                         Gain                              Create                                                             0.49
              NM_001145348   *KDM8*    T           miR-4695-5p    0.42                                                                                                           0.59                               0.44
              NM_001145348   *KDM8*    C           miR-541-3p     0.33                                                                                                           0.77                               0.77
              NM_001145348   *KDM8*    C           miR-654-5p     0.34                                                                                                           0.74                               0.72
              NM_001145348   *KDM8*    C           miR-6769a-5p   0.28                                                                                                                                              0.17
              NM_001145348   *KDM8*    C           miR-6769b-5p   0.27                                                                                                           0.36                               0.32
              NM_001145348   *KDM8*    C           miR-6778-5p    0.22                                                                                                           0.08                               0.59
              NM_001145348   *KDM8*    C           miR-6779-5p    0.39                                                                                                           0.18                               0.13
              NM_001145348   *KDM8*    C           miR-6780a-5p   0.39                                                                                                           0.05                               0.19
              NM_001145348   *KDM8*    C           miR-6785-5p    0.03                                                                                                           0.03                               0.09
              NM_001145348   *KDM8*    C           miR-6799-5p    0.37                                                                                                                                              0.13
              NM_001145348   *KDM8*    C           miR-6883-5p    0.02                                                                                                                                              0.74
              NM_001145348   *KDM8*    C           miR-7106-5p    0.36                                                                                                                                              0.26
              NM_001145348   *KDM8*    C           miR-92a-2-5p   0.40                                                                                                                                              0.60
  rs221347    NM_001184705   *HADH*    T           miR-4729                                                                                      Decrease                                                           0.43
              NM_001184705   *HADH*    T           miR-548g-3p    0.07                                                                           Create                                                             \<0.01
              NM_005327      *HADH*    T           miR-548g-3p    0.07                                                                           Create                                                             \<0.01
              NM_005327      *HADH*    T           miR-4729                                                                                      Decrease                                                           0.43

^a^RefSeq, NCBI or GenBank Transcript/sequence identifiers.

^b^Gene location of variant according to NCBI Genome Build 37 (hg19).

^c^Allele of SNP associated with miRNA--mRNA interaction.

^d^miRBase IDs ([www.mirbase.org](http://www.mirbase.org)) of miRs known or predicted to target-associated gene.

^e^Context+ score differences were curated from the PolymiRTS database. Percentiles were calculated using the entire distribution of context+ score differences available from PolymiRTS.

^f^TCGA-HNSCC miRNA expression from normal (*n* = 44) and tumor (*n* = 523) tissue samples. Expression percentiles for log2-transformed miRNA-mapped reads per million were calculated based on the distribution of all available sequenced miRNAs.

Discussion {#s15}
==========

Previous studies testing the relation of miR-SNPs with HNSCC susceptibility and other cancers have focused on relatively few markers. In addition, miR-SNPs have generally not been well covered by GWAS arrays, making it difficult to accurately impute miR-SNP genotypes from existing data ([@CIT0016]). Here, we employed a genome-scale approach using a novel genotyping platform to determine the contribution of common miR-SNPs to HNSCC susceptibility. We validated eight associations, six of which are in miRNA-related genetic variants. While only a single variant replicated in the analysis of overall HNSCC risk, four replicated in the analysis of oral cavity cancer risk, suggesting effects of miR-SNPs on cancer susceptibility are tissue-specific. All eight variants are located at loci not previously associated with HNSCC risk in the recent and previous GWA studies of HNSCC ([@CIT0012],[@CIT0013]). Genetic variation at validated loci was predicted to disrupt miRNA--mRNA interactions and expression of targeting miRNAs in head and neck tissues was confirmed. Together, these findings suggest miR-SNPs are associated with susceptibility to HNSCC and result in functional changes that contribute to HNSCC tumorigenesis.

The miRNA target site SNPs associated with HNSCC are predicted to alter gene regulation of genes whose role in cancer is supported. *CLEC2D*---a member of the natural killer cell C-type lectin receptors---is an established modulator of the natural killer cell cytotoxic response whose upregulation facilitates immune evasion in glioblastoma ([@CIT0036],[@CIT0037]). Furthermore, the oral cavity cancer risk-associated variant rs7306991 lies within a pseudogene of *CLEC2D*. Pseudogene expression has been suggested to modulate parental gene expression, as competitive endogenous RNAs (ceRNAs), by competing for miRNA binding ([@CIT0038]). *BRAF* pseudogene overexpression has been shown to induce lymphoma in mice ([@CIT0039]), and genetic variation in pseudogenes may disrupt such regulation. Histone demethylase *KDM8* has been implicated in cancer cell proliferation and breast cancer metastasis ([@CIT0040]). Recent work suggests *KDM8* is required for late steps of homologous recombination and genome integrity ([@CIT0043]). Altered *KDM8* expression due to variation at rs1134367 may alter histone methylation and contribute to HNSCC ([@CIT0044]), and several significant eQTL hits for rs1134367 with *KDM8* expression supports this theory. *HADH* is a mitochondrial protein that plays an essential role in long-chain fatty acid β-oxidation (FAO) ([@CIT0045]). *HADH* deficiency results in a rare disorder of mitochondrial FAO ([@CIT0046]). Although located at different genomic loci than *HADH*, expression of the alpha subunit of *HADH* (*HADHA*) is deregulated in clear cell renal cell carcinoma (ccRCC) and has been suggested as a potential prognostic biomarker for ccRCC and lung cancer ([@CIT0047],[@CIT0048]). Furthermore, fatty acid metabolism is now regarded as a key contributor to cancer cell proliferation ([@CIT0049]), therefore it is plausible that deregulation of miRNA-mediated expression of *HADH* by rs221347 may contribute to carcinogenesis.

Given that previous studies investigating the roles of miR-SNPs in HNSCC risk have been limited to candidate-based approaches, the large scale of our study represents a major strength. Furthermore, use of two independent study populations allowed us to validate our findings and reduce the likelihood of false positive associations. Despite these strengths, our study has some underlying limitations. The tools for miRNA target site prediction are limited by our incomplete knowledge of the principles for functional miRNA targeting, which remains controversial ([@CIT0050]). Consequently, our approach is insensitive to yet unidentified genetic variants that may occur in miRNA targets and alter risk of HNSCC. Additionally, relative to most GWA studies, our sample size is modest and replication in larger, more ethnically diverse populations is warranted. Differing demographic and clinical characteristic structures between the populations used in this study, as well as the presence of potential gene-gene interactions that may contribute to HNSCC susceptibility, which were not considered in this study, may have also reduced our ability to identify true associations. Furthermore, given the etiologic importance of HPV infection for oropharyngeal cancers, lack of adjustment for HPV positivity in the validation phase and joint population analyses of pharyngeal cancer risk may have contributed to non-replication observed in this subgroup. Future studies with more complete HPV data are needed to confirm our findings. Finally, where it did not already exist, functional studies of the variant genotypes identified here are needed to further understand the biology of observed associations and discount the potential contribution of other functional variants in LD. However, miR-SNPs are empirically in low LD with variants included on many GWAS panels, strengthening our findings.

In summary, we identified and validated miR-SNPs associated with risk of HNSCC. As our understanding of miRNA biology grows and novel miRNA target site prediction algorithms are developed, additional miR-SNPs may be identified. Here we demonstrated the utility of current knowledge to functionally annotate miR-SNPs associated with HNSCC.
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